Galera Therapeutics Files Definitive Proxy Statement

TL;DR

Galera Therapeutics filed its proxy statement for the annual meeting. Shareholders vote on company matters.

AI Summary

Galera Therapeutics, Inc. filed its definitive proxy statement on January 24, 2025, for its annual meeting. The filing, under the 1934 Act, concerns the solicitation of proxies from shareholders. The company is based in Malvern, PA, and operates in the pharmaceutical preparations sector.

Why It Matters

This filing is crucial for shareholders as it outlines the agenda and proposals for the company's annual meeting, allowing them to exercise their voting rights.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEF 14A) for an annual meeting and does not contain new material financial or operational information.

Key Numbers

• 20250124 — Filing Date (The date the definitive proxy statement was filed with the SEC.)
• 20250224 — Report Period End Date (The period the proxy statement pertains to, likely the fiscal year ending before the annual meeting.)

Key Players & Entities

• Galera Therapeutics, Inc. (company) — Registrant
• 101 Lindenwood Drive, Suite 225, Malvern, PA 19355 (location) — Business and Mail Address
• 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations

FAQ

Key Financial Figures

• $0.001 — f record of shares of our common stock, $0.001 par value per share, as of the close of

Filing Documents

• d904642ddef14a.htm (DEF 14A) — 314KB
• g904642g00q00.jpg (GRAPHIC) — 219KB
• g904642g00w00.jpg (GRAPHIC) — 234KB
• g904642g01g01.jpg (GRAPHIC) — 37KB
• g904642g03l16.jpg (GRAPHIC) — 26KB
• g904642g05a44.jpg (GRAPHIC) — 36KB
• g904642g12r13.jpg (GRAPHIC) — 20KB
• 0001193125-25-011837.txt ( ) — 1092KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 28 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 30 STOCKHOLDERS PROPOSALS 33 OTHER MATTERS 34 SOLICITATION OF PROXIES 35 GALERAS ANNUAL REPORT ON FORM 10-K 36 GALERA THERAPEUTICS, INC. 101 Lindenwood Drive, Suite 225 Malvern, Pennsylvania 19355 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD MONDAY, FEBRUARY 24, 2025 The Annual Meeting of Stockholders (the Annual Meeting) of Galera Therapeutics, Inc., a Delaware corporation (the Company), will be held at 10:00 a.m. Eastern time on Monday, February 24, 2025. The Annual Meeting will be a completely virtual meeting, which will be conducted via live webcast. You will be able to attend the Annual Meeting online and submit your questions during the meeting by visiting www.virtualshareholdermeeting.com/GRTX2024 and entering your 16-digit control number included on your proxy card or on the instructions that accompanied your proxy materials. The Annual Meeting will be held for the following purposes: To elect Lawrence Alleva and Kevin Lokay as Class II Directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified; To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; and To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment of the Annual Meeting. Holders of record of our common stock as of the close of business on January 22, 2025 are entitled to notice of and to vote at the Annual Meeting, or any continuation, postponement or adjournment of the Annual Meeting. A complete list of such stockholders will be open to the examination of any stockholder for a period of ten days prior to the Annual Meeting for a purpose germane to the meeting by contacting our corporate secret

View Full Filing

View this DEF 14A filing on SEC EDGAR